Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1996 Mar 19;93(6):2398–2402. doi: 10.1073/pnas.93.6.2398

Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.

G Halmos 1, A V Schally 1, J Pinski 1, M Vadillo-Buenfil 1, K Groot 1
PMCID: PMC39808  PMID: 8637885

Abstract

Antagonists of luteinizing hormone-releasing hormone (LH-RH), unlike the LH-RH agonists, suppress gonadotropins and sex steroid secretion immediately after administration, without initial stimulatory effects. [Ac-D-Nal(2)1,D-Ph(4Cl)2,D-Pal(3)3,D-Cit6,D-Ala10]LH-R H (SB-75; Cetrorelix) is a modern, potent antagonistic analog of LH-RH. In this study, the binding characteristics of receptors for LH-RH in membrane fractions from rat anterior pituitaries were investigated after a single injection of Cetrorelix at a dose of 100 microg per rat. To determine whether the treatment with Cetrorelix can affect the concentration of measurable LH-RH binding sites, we applied an in vitro method to desaturate LH-RH receptors by chaotropic agents such as manganous chloride (MnCl2) and ammonium thiocyanate (NH4SCN). Our results show that the percentages of occupied LH-RH receptors at 1, 3, and 6 h after administration of Cetrorelix were approximately 28%, 14%, and 10%, respectively, of total receptors. At later time intervals, we could not detect occupied LH-RH binding sites. Ligand competition assays, following in vitro desaturation, demonstrated that rat pituitary LH-RH receptors were significantly (P < 0.01) down-regulated for at least 72 h after administration of Cetrorelix. The lowest receptor concentration was found 3-6 h after Cetrorelix treatment and a recovery in receptor number began within approximately 24 h. The down-regulation of LH-RH binding sites induced by Cetrorelix was accompanied by serum LH and testosterone suppression. Higher LH-RH receptor concentrations coincided with elevated serum hormone levels at later time intervals. Our results indicate that administration of LH-RH antagonist Cetrorelix produces a marked down-regulation of pituitary receptors for LH-RH and not merely an occupancy of binding sites.

Full text

PDF
2400

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bajusz S., Csernus V. J., Janaky T., Bokser L., Fekete M., Schally A. V. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res. 1988 Dec;32(6):425–435. doi: 10.1111/j.1399-3011.1988.tb01373.x. [DOI] [PubMed] [Google Scholar]
  2. Bajusz S., Kovacs M., Gazdag M., Bokser L., Karashima T., Csernus V. J., Janaky T., Guoth J., Schally A. V. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1637–1641. doi: 10.1073/pnas.85.5.1637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Behre H. M., Klein B., Steinmeyer E., McGregor G. P., Voigt K., Nieschlag E. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men. J Clin Endocrinol Metab. 1992 Aug;75(2):393–398. doi: 10.1210/jcem.75.2.1639941. [DOI] [PubMed] [Google Scholar]
  4. Bokser L., Srkalovic G., Szepeshazi K., Schally A. V. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75). Neuroendocrinology. 1991 Aug;54(2):136–145. doi: 10.1159/000125862. [DOI] [PubMed] [Google Scholar]
  5. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  6. Conn P. M., Crowley W. F., Jr Gonadotropin-releasing hormone and its analogues. N Engl J Med. 1991 Jan 10;324(2):93–103. doi: 10.1056/NEJM199101103240205. [DOI] [PubMed] [Google Scholar]
  7. Emons G., Schally A. V. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod. 1994 Jul;9(7):1364–1379. doi: 10.1093/oxfordjournals.humrep.a138714. [DOI] [PubMed] [Google Scholar]
  8. Fekete M., Bajusz S., Groot K., Csernus V. J., Schally A. V. Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes. Endocrinology. 1989 Feb;124(2):946–955. doi: 10.1210/endo-124-2-946. [DOI] [PubMed] [Google Scholar]
  9. Gonzalez-Barcena D., Vadillo-Buenfil M., Cortez-Morales A., Fuentes-Garcia M., Cardenas-Cornejo I., Comaru-Schally A. M., Schally A. V. Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology. 1995 Feb;45(2):275–281. doi: 10.1016/0090-4295(95)80018-2. [DOI] [PubMed] [Google Scholar]
  10. Gonzalez-Barcena D., Vadillo-Buenfil M., Gomez-Orta F., Fuentes Garcia M., Cardenas-Cornejo I., Graef-Sanchez A., Comaru-Schally A. M., Schally A. V. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate. 1994;24(2):84–92. doi: 10.1002/pros.2990240206. [DOI] [PubMed] [Google Scholar]
  11. Gordon K. Terminology for GnRH antagonists. Fertil Steril. 1994 May;61(5):994–995. doi: 10.1016/s0015-0282(16)56723-5. [DOI] [PubMed] [Google Scholar]
  12. Halmos G., Rekasi Z., Szoke B., Schally A. V. Use of radioreceptor assay and cell superfusion system for in vitro screening of analogs of growth hormone-releasing hormone. Receptor. 1993 Summer;3(2):87–97. [PubMed] [Google Scholar]
  13. Hatefi Y., Hanstein W. G. Destabilization of membranes with chaotropic ions. Methods Enzymol. 1974;31:770–790. doi: 10.1016/0076-6879(74)31080-4. [DOI] [PubMed] [Google Scholar]
  14. Hatefi Y., Hanstein W. G. Solubilization of particulate proteins and nonelectrolytes by chaotropic agents. Proc Natl Acad Sci U S A. 1969 Apr;62(4):1129–1136. doi: 10.1073/pnas.62.4.1129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Karten M. J., Rivier J. E. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev. 1986 Feb;7(1):44–66. doi: 10.1210/edrv-7-1-44. [DOI] [PubMed] [Google Scholar]
  16. Kelly P. A., Leblanc G., Djiane J. Estimation of total prolactin-binding sites after in vitro desaturation. Endocrinology. 1979 Jun;104(6):1631–1638. doi: 10.1210/endo-104-6-1631. [DOI] [PubMed] [Google Scholar]
  17. Leroy I., d'Acremont M., Brailly-Tabard S., Frydman R., de Mouzon J., Bouchard P. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge. Fertil Steril. 1994 Sep;62(3):461–467. doi: 10.1016/s0015-0282(16)56932-5. [DOI] [PubMed] [Google Scholar]
  18. Mason D. R., Arora K. K., Mertz L. M., Catt K. J. Homologous down-regulation of gonadotropin-releasing hormone receptor sites and messenger ribonucleic acid transcripts in alpha T3-1 cells. Endocrinology. 1994 Sep;135(3):1165–1170. doi: 10.1210/endo.135.3.8070359. [DOI] [PubMed] [Google Scholar]
  19. McPherson G. A. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Methods. 1985 Nov;14(3):213–228. doi: 10.1016/0160-5402(85)90034-8. [DOI] [PubMed] [Google Scholar]
  20. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  21. Perheentupa A., Huhtaniemi I. Gonadotropin gene expression and secretion in gonadotropin-releasing hormone antagonist-treated male rats: effect of sex steroid replacement. Endocrinology. 1990 Jun;126(6):3204–3209. doi: 10.1210/endo-126-6-3204. [DOI] [PubMed] [Google Scholar]
  22. Pinski J., Yano T., Groot K., Milovanovic S., Schally A. V. Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats. Peptides. 1992 Sep-Oct;13(5):905–911. doi: 10.1016/0196-9781(92)90048-8. [DOI] [PubMed] [Google Scholar]
  23. Pinski J., Yano T., Szepeshazi K., Groot K., Schally A. V. Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix (SB-75). J Androl. 1993 May-Jun;14(3):164–169. [PubMed] [Google Scholar]
  24. Sandow J., Von Rechenberg W., Jerzabek G., Stoll W. Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone. Fertil Steril. 1978 Aug;30(2):205–209. doi: 10.1016/s0015-0282(16)43461-8. [DOI] [PubMed] [Google Scholar]
  25. Schally A. V., Arimura A., Kastin A. J., Matsuo H., Baba Y., Redding T. W., Nair R. M., Debeljuk L., White W. F. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science. 1971 Sep 10;173(4001):1036–1038. doi: 10.1126/science.173.4001.1036. [DOI] [PubMed] [Google Scholar]
  26. Schally A. V. Hypothalamic hormones: from neuroendocrinology to cancer therapy. Anticancer Drugs. 1994 Apr;5(2):115–130. [PubMed] [Google Scholar]
  27. Srkalovic G., Bokser L., Radulovic S., Korkut E., Schally A. V. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75. Endocrinology. 1990 Dec;127(6):3052–3060. doi: 10.1210/endo-127-6-3052. [DOI] [PubMed] [Google Scholar]
  28. Szöke B., Horváth J., Halmos G., Rékási Z., Groot K., Nagy A., Schally A. V. LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro. Peptides. 1994;15(2):359–366. doi: 10.1016/0196-9781(94)90024-8. [DOI] [PubMed] [Google Scholar]
  29. Vickery B. H. Comparison of the potential for therapeutic utilities with gonadotropin-releasing hormone agonists and antagonists. Endocr Rev. 1986 Feb;7(1):115–124. doi: 10.1210/edrv-7-1-115. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES